Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021

References

• Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):1–8. doi:10.1056/nejmoa2104840.
   PubMed Web of Science ®Google Scholar
• Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, Wiedmann M, Aamodt AH, Skattør TH, Tjønnfjord GE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021 June 3;384(22):2124–2130. doi:10.1056/NEJMoa2104882.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control (ECDC). Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA. 2021 May 6 [accessed 2023 Jan 21]. https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-overview-vaccination-strategies-deployment-plans-6-may-2021.pdf.
   Google Scholar
• Shaw RH, Stuart A, Greenland M, Liu X, Nguyen Van-Tam JS, Snape MD, Com-COV Study Group. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021;397(10289):2043–2046. doi:10.1016/S0140-6736(21)01115-6.
   PubMed Web of Science ®Google Scholar
• Powell AA, Power L, Westrop S, McOwat K, Campbell H, Simmons R, Ramsay ME, Brown K, Ladhani SN, Amirthalingam G. Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England. Euro Surveill. 2021;26(28):2100634. doi:10.2807/1560-7917.es.2021.26.28.2100634. Erratum in: Euro Surveill. 2022;27(8):220224e.
   PubMedGoogle Scholar
• Clari M, Godono A, Albanesi B, Casabona E, Comoretto RI, Mansour I, Conti A, Dimonte V, Ciocan C. Choosing between homologous or heterologous COVID-19 vaccination regimens: a cross-sectional study among the general population in Italy. Int J Environ Res Public Health. 2022;19(5):2944. doi:10.3390/ijerph19052944.
   PubMed Web of Science ®Google Scholar
• Ministero della Salute. Aggiornamento parere CTS vaccini. 2021 June 11 [accessed 2023 Jan 21]. https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2021&codLeg=81053&parte=1%20&serie=null.
   Google Scholar
• Bánki Z, Mateus J, Rössler A, Schäfer H, Bante D, Riepler L, Grifoni A, Sette A, Simon V, Falkensammer B, et al. Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: the pragmatic, multi-center, three-arm, partially randomized HEVACC trial. EBioMedicine. 2022;80:104073. doi:10.1016/2Fj.ebiom.2022.104073.
   PubMed Web of Science ®Google Scholar
• Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J, Campins M, Portolés A, González-Pérez M, García Morales MT, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021;398(10295):121–130. doi:10.1016/2FS0140-6736(21)01420-3.
   PubMed Web of Science ®Google Scholar
• Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, Cameron JC, Charlton S, Clutterbuck EA, Collins AM, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021;398(10303):856–869. doi:10.1016/2FS0140-6736(21)01694-9.
   PubMed Web of Science ®Google Scholar
• Normark J, Vikström L, Gwon YD, Persson IL, Edin A, Björsell T, Dernstedt A, Christ W, Tevell S, Evander M, et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination. N Engl J Med. 2021;385(11):1049–1051. doi:10.1056/2FNEJMc2110716.
   PubMed Web of Science ®Google Scholar
• Stuart ASV, Shaw RH, Liu X, Greenland M, Aley PK, Andrews NJ, Cameron JC, Charlton S, Clutterbuck EA, Collins AM, et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet. 2022;399(10319):36–49. doi:10.1016/s0140-6736(21)02718-5.
   PubMed Web of Science ®Google Scholar
• Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C, Jentzsch S, Helbig ET, Lippert LJ, Tscheak P, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med. 2021;9(11):1255–1265. doi:10.1016/2FS2213-2600(21)00357-X.
   PubMed Web of Science ®Google Scholar
• Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S, Abu-Omar A, Ziegler L, Guckelmus C, Urschel R, et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med. 2021;27(9):1530–5. doi:10.1038/2Fs41591-021-01464-w.
   PubMed Web of Science ®Google Scholar
• Sheng WH, Chang SY, Lin PH, Hsieh MJ, Chang HH, Cheng CY, Yang HC, Pan CF, Ieong SM, Chao TL, et al. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination. J Formos Med Assoc. 2022;121(4):766–777. doi:10.1016/j.jfma.2022.02.020.
   PubMed Web of Science ®Google Scholar
• Warkentin L, Zeschick N, Kühlein T, Steininger P, Überla K, Kaiser I, Gall C, Sebastião M, Hueber S. Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort study. BMC Infect Dis. 2022;22(1):504. doi:10.1186/s12879-022-07443-x.
   PubMed Web of Science ®Google Scholar
• Nordström P, Ballin M, Nordström A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: a nationwide cohort study. Lancet Reg Health Eur. 2021;11:100249. doi:10.1016/j.lanepe.2021.100249.
   PubMedGoogle Scholar
• Agenzia Italiana del Farmaco. Rapporto annuale sulla sicurezza dei vaccini anti-COVID-19 27/12/2020-26/12/2021. 2022 Feb 9 [accessed 2023 Jan 21]. https://www.aifa.gov.it/documents/20142/1315190/Rapporto_annuale_su_sicurezza_vaccini%20anti-COVID-19.pdf.
   Google Scholar
• Benning L, Töllner M, Hidmark A, Schaier M, Nusshag C, Kälble F, Reichel P, Buylaert M, Grenz J, Ponath G, et al. Heterologous ChAdOx1 nCoV-19/BNT162b2 prime-boost vaccination induces strong humoral responses among health care workers. Vaccines. 2021;9(8):857. doi:10.3390/vaccines9080857.
   Web of Science ®Google Scholar
• Tenbusch M, Schumacher S, Vogel E, Priller A, Held J, Steininger P, Beileke S, Irrgang P, Brockhoff R, Salmanton-García J, et al. Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. Lancet Infect Dis. 2021;21(9):1212–1213. doi:10.1016/2FS1473-3099(21)00420-5.
   PubMed Web of Science ®Google Scholar
• Firinu D, Perra A, Campagna M, Littera R, Meloni F, Sedda F, Conti M, Costanzo G, Erbi M, Usai G, et al. Evaluation of antibody response to heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2: an observational study. Vaccines (Basel). 2021;9(12):1478. doi:10.3390/2Fvaccines9121478.
   PubMed Web of Science ®Google Scholar
• US Centers for Disease Control and Prevention (CDC). V-safe after vaccination health checker - v-safe protocol version 2. 2021 Jan 28 [accessed 2023 Mar 27]. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html and https://www.cdc.gov/vaccinesafety/pdf/V-safe-Protocol-v2-012821.pdf.
   Google Scholar
• Machin D, Campbell MJ, Tan SB, Tan SH. Post-marketing surveillance. In: Wiley-Blackwell A, editor. Sample size tables for clinical studies. 3rd ed. Hoboken (NJ): John Wiley & Sons, Ltd., Publication; 2009. p. 142–52.
   Google Scholar
• European Medicines Agency (EMA). Comirnaty – product information. 2020 May 6 [accessed 2023 Jan 21]. https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf.
   Google Scholar
• Li J, Hou L, Guo X, Jin P, Wu S, Zhu J, Pan H, Wang X, Song Z, Wan J, et al. Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. Nat Med. 2022;28(2):401–9. doi:10.1038/s41591-021-01677-z.
   PubMed Web of Science ®Google Scholar
• Wanlapakorn N, Suntronwong N, Phowatthanasathian H, Yorsaeng R, Vichaiwattana P, Thongmee T, Auphimai C, Srimuan D, Thatsanatorn T, Assawakosri S, et al. Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study. Human Vacc Immunother. 2022;18(1):2029111. doi:10.1080/21645515.2022.2029111.
   PubMed Web of Science ®Google Scholar